ATE522531T1 - Indolylpyrrolidine zur behandlung von krebs - Google Patents

Indolylpyrrolidine zur behandlung von krebs

Info

Publication number
ATE522531T1
ATE522531T1 AT08771523T AT08771523T ATE522531T1 AT E522531 T1 ATE522531 T1 AT E522531T1 AT 08771523 T AT08771523 T AT 08771523T AT 08771523 T AT08771523 T AT 08771523T AT E522531 T1 ATE522531 T1 AT E522531T1
Authority
AT
Austria
Prior art keywords
present
cancer
pyrrolidine
indolylpyrrolidine
treatment
Prior art date
Application number
AT08771523T
Other languages
English (en)
Inventor
Neil Westlund
Jason Hill
Mark Ashwell
Nivedita Namdev
Jianqiang Wang
Syed Ali
Original Assignee
Arqule Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Arqule Inc filed Critical Arqule Inc
Application granted granted Critical
Publication of ATE522531T1 publication Critical patent/ATE522531T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/06—Peri-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT08771523T 2007-06-22 2008-06-19 Indolylpyrrolidine zur behandlung von krebs ATE522531T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US94582007P 2007-06-22 2007-06-22
PCT/US2008/067566 WO2009002807A2 (en) 2007-06-22 2008-06-19 Indolyl pyrrolidines for the treatment of cancer

Publications (1)

Publication Number Publication Date
ATE522531T1 true ATE522531T1 (de) 2011-09-15

Family

ID=39767054

Family Applications (1)

Application Number Title Priority Date Filing Date
AT08771523T ATE522531T1 (de) 2007-06-22 2008-06-19 Indolylpyrrolidine zur behandlung von krebs

Country Status (8)

Country Link
US (1) US8513292B2 (de)
EP (2) EP2173748B1 (de)
JP (2) JP5490688B2 (de)
CN (1) CN101801969B (de)
AT (1) ATE522531T1 (de)
CA (2) CA2912546A1 (de)
TW (1) TWI421251B (de)
WO (1) WO2009002807A2 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101801961B (zh) * 2007-06-22 2014-09-24 艾科尔公司 吡咯烷酮、吡咯烷-2,5-二酮、吡咯烷和硫代琥珀酰亚胺衍生物、组合物以及治疗癌症的方法
AU2010336533B9 (en) * 2009-12-23 2015-10-08 Arqule, Inc. Purified pyrroloquinolinyl-pyrrolidine-2,5-dione compositions and methods for preparing and using same
US8563567B2 (en) 2009-12-30 2013-10-22 Arqule, Inc. Substituted heterocyclic compounds
EP2655372B8 (de) * 2010-12-23 2016-09-07 ArQule, Inc. Pyrrolochinolinyl-pyrrolidin-2,5-dion-zusammensetzungen und verfahren zu ihrer herstellung und verwendung
US9216998B2 (en) 2012-02-15 2015-12-22 Janssen Pharmaceutica Nv Tricyclic indole derivatives useful endothelial lipase inhibitors
CN103626762B (zh) * 2012-08-24 2015-07-29 上海医药工业研究院 苯并吡啶氮杂卓类化合物及其应用
CN113845961B (zh) * 2021-10-11 2022-08-12 山东三品新能源有限公司 一种齿轮用润滑油组合物及其制备方法

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US36736A (en) * 1862-10-21 Improvement in curry-combs
US4522811A (en) 1982-07-08 1985-06-11 Syntex (U.S.A.) Inc. Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides
SK278989B6 (sk) 1988-02-10 1998-05-06 F. Hoffmann-La Roche Ag Substituované pyroly, ich použitie na výrobu lieči
USRE36736E (en) 1989-02-06 2000-06-13 Hoffman-La Roche Inc. Substituted pyrroles
MC2096A1 (fr) 1989-02-23 1991-02-15 Hoffmann La Roche Pyrroles substitues
GB8904161D0 (en) * 1989-02-23 1989-04-05 Hoffmann La Roche Substituted pyrroles
PT93947B (pt) 1989-05-05 1996-11-29 Goedecke Ag Processo para a preparacao de novos derivados de maleinimidas e de composicoes farmaceuticas que os contem
US5380746A (en) 1989-05-05 1995-01-10 Goedecke Aktiengesellschaft Bis-(1H-indol-3-YL)-maleinimide derivatives, processes for the preparation thereof and pharmaceutical compositions containing them
DE4005970A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte maleinimide, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
DE4005969A1 (de) 1990-02-26 1991-08-29 Boehringer Mannheim Gmbh Neue trisubstituierte pyrrole, verfahren zu ihrer herstellung sowie arzneimittel, die diese verbindungen enthalten
US5292747A (en) 1990-08-07 1994-03-08 Hoffman-La Roche Inc. Substituted pyrroles
US5591842A (en) 1991-11-29 1997-01-07 Banyu Pharmaceutical Co., Ltd. Indolopyrrolocarbazole derivatives
EP0630241A1 (de) 1992-03-20 1994-12-28 The Wellcome Foundation Limited Indolderivate mit antiviraler wirkung
US5721230A (en) 1993-05-10 1998-02-24 Hoffmann-La Roche Inc. Substituted pyrroles
PT817627E (pt) 1993-12-23 2005-07-29 Lilly Co Eli Inibidores da proteina cinase c
US5545636A (en) 1993-12-23 1996-08-13 Eli Lilly And Company Protein kinase C inhibitors
US6524832B1 (en) 1994-02-04 2003-02-25 Arch Development Corporation DNA damaging agents in combination with tyrosine kinase inhibitors
WO1995030682A1 (fr) 1994-05-09 1995-11-16 Banyu Pharmaceutical Co., Ltd. Derive d'indolopyrolocarbazole antitumoral
US5591855A (en) 1994-10-14 1997-01-07 Cephalon, Inc. Fused pyrrolocarbazoles
US5559228A (en) 1995-03-30 1996-09-24 Eli Lilly And Company Synthesis of bisindolylmaleimides
CA2249205A1 (en) 1996-03-20 1997-09-25 Eli Lilly And Company Synthesis of indolylmaleimides
PE91598A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
PE91698A1 (es) 1996-07-29 1998-12-24 Hoffmann La Roche Pirroles sustituidos
HUP0003203A3 (en) 1996-08-23 2002-01-28 Lilly Co Eli Process for producing bisindolymalimides
SE9603283D0 (sv) 1996-09-10 1996-09-10 Astra Ab New compounds
AU4920397A (en) 1996-10-11 1998-05-11 Chiron Corporation Purine inhibitors of glycogen synthase kinase 3 (gsk3)
US5859261A (en) 1997-03-20 1999-01-12 Eli Lilly And Company Synthesis of indolylmaleimides
IL141080A0 (en) 1998-07-30 2002-02-10 Japan Tobacco Inc Disubstituted maleimide derivatives and pharmaceutical compositions containing the same
AU2327700A (en) 1999-02-09 2000-08-29 Rei Asakai Pyrrole derivatives and cell death inhibitors
US6867198B2 (en) 1999-12-16 2005-03-15 Eli Lilly And Company Agents and methods for the treatment of proliferative diseases
EP1250334B1 (de) 1999-12-16 2004-05-19 Eli Lilly And Company Medikamente geeignet zur Behandlung von proliferativen Erkrankungen
WO2001074807A1 (fr) 2000-03-30 2001-10-11 Sagami Chemical Research Center Derives indolylpyrrole et inhibiteurs de mort cellulaire
RU2294931C2 (ru) 2000-05-11 2007-03-10 Консехо Супериор Инвестигасионес Сьентификас Гетероциклические ингибиторы гликоген-синтазы киназы gsk-3
AU7785401A (en) 2000-06-29 2002-01-14 Long Island Jewish Res Inst Modulators of cellular proliferation and angiogenesis, methods for use and identification thereof
AU2003219679B2 (en) 2002-01-23 2009-02-26 Texas Tech University Mammalian migration inducting gene and methods for detection and inhibition of migrating tumor cells
ATE346070T1 (de) 2002-03-05 2006-12-15 Lilly Co Eli Purinderivate als kinaseinhibitoren
US20070059697A1 (en) 2003-04-15 2007-03-15 Avalon Pharmaceuticals, Inc Determining cancer-linked genes and therapeutic targets using molecular cytogenetic methods
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
PL1636593T3 (pl) 2003-06-06 2009-08-31 Genentech Inc Modulowanie oddziaływania pomiędzy łańcuchem beta HGF i c-met.
WO2005007193A2 (en) 2003-07-07 2005-01-27 Vande Woude, George, F. Inhibition of tumor angiogenesis by combination of thrombospondin-1 and inhibitors of vascular endothelial growth factor
AU2004298483A1 (en) 2003-12-11 2005-06-30 Genentech, Inc. Methods and compositions for inhibiting c-met dimerization and activation
PL1846406T3 (pl) * 2005-02-09 2011-04-29 Arqule Inc Pochodne imidowe kwasu maleinowego, kompozycje farmaceutyczne i sposoby leczenia nowotworów
KR20140068234A (ko) 2005-03-31 2014-06-05 더 제너럴 하스피탈 코포레이션 Ｈｇｆ／ｈｇｆｒ 활성의 모니터링 및 조정
CN101801961B (zh) * 2007-06-22 2014-09-24 艾科尔公司 吡咯烷酮、吡咯烷-2,5-二酮、吡咯烷和硫代琥珀酰亚胺衍生物、组合物以及治疗癌症的方法

Also Published As

Publication number Publication date
WO2009002807A3 (en) 2009-07-30
JP2013241458A (ja) 2013-12-05
US8513292B2 (en) 2013-08-20
CA2690782C (en) 2016-02-02
US20100183603A1 (en) 2010-07-22
EP2392574B1 (de) 2013-12-18
JP5490688B2 (ja) 2014-05-14
CA2912546A1 (en) 2008-12-31
EP2173748B1 (de) 2011-08-31
WO2009002807A2 (en) 2008-12-31
CN101801969B (zh) 2014-10-29
CN101801969A (zh) 2010-08-11
EP2392574A1 (de) 2011-12-07
EP2173748A2 (de) 2010-04-14
JP5792239B2 (ja) 2015-10-07
JP2010530884A (ja) 2010-09-16
CA2690782A1 (en) 2008-12-31
TWI421251B (zh) 2014-01-01
TW200918530A (en) 2009-05-01

Similar Documents

Publication Publication Date Title
DE602006017965D1 (de) Maleimid-derivate, pharmazeutische zusammensetzungen und verfahren zur behandlung von krebs
UA107783C2 (en) Isoindoline compounds for use in treating cancer
EA201100119A1 (ru) Химические соединения 251
MX2011006959A (es) Compuestos substituidos de 5,6-dihidro-6-fenilbenzo [f] isoquinolina-2-amina.
EA201170670A1 (ru) Аминотетрагидропираны в качестве ингибиторов дипептидилпептидазы-iv для лечения или предупреждения диабета
MX2009008439A (es) Nuevos inhibidores de la replicacion del virus de hepatitis c.
ATE522531T1 (de) Indolylpyrrolidine zur behandlung von krebs
EA201001196A1 (ru) Соединения 4-пиридинона и их применение для лечения рака
EA200700501A1 (ru) Композиция (варианты) и способ для лечения гиперпролиферативных процессов, способ лечения рака (варианты) и способ получения твёрдой дисперсии вещества
EA200870415A1 (ru) Хиназолины для ингибирования pdk 1
EA200971026A1 (ru) Новые макроциклические ингибиторы репликации вируса гепатита с
EA200971041A1 (ru) Новые пептидные ингибиторы репликации вируса гепатита с
EA201001639A1 (ru) Композиции и способы их получения и применения
EA201290919A1 (ru) Индазольные соединения и их применение
MX2009013815A (es) Compuestos de quinazolinona y metodos de uso para los mismos.
EA200901212A1 (ru) 3-имидазолилиндолы, предназначенные для лечения пролиферативных заболеваний
EA201071045A1 (ru) Соединения оксадиазоантрацена для лечения диабета
MY157124A (en) Substituted imidazopyridinyl-aminopyridine compounds
ATE395905T1 (de) Pharmazeutische zusammensetzungen in form fester dispersionen zur behandlung von krebs
EA201001865A1 (ru) Противовоспалительные агенты
WO2009026446A8 (en) Hdac inhibitors
EA201001094A1 (ru) Производные индазола
ATE522500T1 (de) Amidderivate als ionenkanalliganden sowie pharmazeutische zusammensetzungen und verwendungsverfahren dafür
ATE538105T1 (de) Substituierte tetrazolverbindungen und ihre verwendung
EA201201404A1 (ru) Триазолы как ингибиторы кбв (кинезин-белок веретена)

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties